Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585822 | 0.94 | KCNQ3 (0.41) | KCNQ3KCNQ2PTGDR2RORCS1PR2 | |
| SCHEMBL585990 | 0.90 | PTGDR2 (0.44) | KCNQ3KCNQ2PTGDR2RORCPPARG | |
| SCHEMBL585444 | 0.85 | RORC (0.44) | PTGDR2RORC | |
| SCHEMBL586124 | 0.83 | PTGDR2 (0.47) | KCNQ3KCNQ2PTGDR2NR3C1 | |
| SCHEMBL585257 | 0.83 | PTGDR2 (0.46) | KCNQ3KCNQ2PTGDR2RORC | |
| SCHEMBL585958 | 0.80 | PTGDR2 (0.48) | KCNQ3KCNQ2PTGDR2RORC | |
| SCHEMBL586021 | 0.80 | PTGDR2 (0.44) | KCNQ3KCNQ2PTGDR2RORCS1PR2 | |
| SCHEMBL585786 | 0.78 | SLC22A12 (0.41) | KCNQ3KCNQ2PTGDR2 | |
| SCHEMBL585820 | 0.78 | KCNQ3 (0.45) | KCNQ3KCNQ2PTGDR2RORCALDH1A1 | |
| SCHEMBL587042 | 0.78 | EPAS1 (0.42) | PTGDR2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963259-B1 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | claimed |
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| EP-1963259-B1 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| EP-2305640-A2 | Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305640-A2 | Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007068894-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | PNMT, SQOR, SMS | KCNQ3 912/4885KCNQ2 970/4885PTGDR2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.